UPC APP 17607/2025

—·EP4183412: RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Rücknahmeanträge
Parteien: Kläger
Pfizer, Inc.
Pfizer Europe MA EEIG
Pfizer B.V.
Pfizer S.A.
Pfizer Manufacturing Belgium NV
Pfizer Service Company S.R.L.
Pfizer Pharma GmbH
Pfizer Limited
Vertreter: Gareth Williams
Beklagte
GlaxoSmithKline Biologicals SA
Vertreter: Oliver Jan Juengst; Daniela Kinkeldey
Division: Milan CD
Richter: Andrea Postiglione · Presiding Judge
Anna-Lena Klein · Judge-rapporteur
Steen Wadskov-Hansen · Technically Qualified Judge
Technology: Biotechnology
Sprache: —
Erste Entscheidung: 22. Apr. 2025

Entscheidungen

2025-04-22
ZurückgenommenApplication Rop 265
The Milan Central Division allowed Pfizer's withdrawal of both the revocation action (ACT_45928/2024) and the counterclaim for revocation (CC_60908/2024) against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV vaccine patent), with GSK's consent and without a cost decision; 60% of court fees were reimbursed to Pfizer.
Rechtsfragen:Withdrawal of revocation action (R. 265 RoP)Court fee reimbursementRSV vaccine patent

Dokumente